You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
uniQure Returns vs. S&P
|1 Year||5 Year||5 Year Annualized||Since IPO|
uniQure Company Info
News & Analysis
A big approval for a gene therapy sent the biotech's stock higher.
The company is temporarily delaying higher-dose procedures of experimental gene therapy AMT-130.
It just reported a packet of promising safety data for its flagship pipeline program.
Several drugmakers have important clinical trial updates on the way.
A clinical hold is weighing on the biotech's shares today.
Agreement licenses the rights for a promising hemophilia B gene therapy.
Here are the biotechs most likely to receive juicy buyout offers in 2020.
Investor optimism is surging following recent M&A in gene therapy.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.